January 23, 2008 -- Sinovac Biotech Ltd. (AMEX: SVA), a Beijing based developer of vaccines, placed 2.5 million shares with a single accredited investor, raising $9.75 million in gross proceeds. The price was $3.90 per share, a slight increase over the closing price of Sinovac yesterday of $3.76. At its current price, Sinovac has a trailing 12 months P/E ratio of 25 and a market capitalization of $149 million. Revenues for the first nine months of 2007 are increasing at a 160% rate over 2006, and the company made a nine-month profit of $5.7 million on $24.3 million of revenue, a margin of 23%. More details...
